On August 9, 2026, in Shanghai, an innovation-focused biopharmaceutical company named Mabwell, listed as 688062 on the Shanghai Stock Exchange and 02493 on the Hong Kong Stock Exchange, revealed that its subsidiary T-mab has cleared the Good Manufacturing Practice (GMP) inspection conducted by the Brazilian Health Regulatory Agency (ANVISA). This accomplishment signifies a major milestone for the company's operations in Brazil.